Curis Posts $8.1M Q3 Loss, Zero Revenue; Cash Lasts Into Q1 2027
CRIS sits 76% above its 52-week low of $0.325 on light trading volume (0.1× avg).
Summary
Curis reported a Q3 net loss of $8.1M versus $7.7M a year earlier, with revenue at zero against $3.2M in Q3 2025 after the 2025 sale of Erivedge royalties. The nine-month loss widened to $40.9M from $26.9M, and the company held just $5.0M in cash at September 30. Management says the roughly $7.5M in net October placement proceeds stretch the runway into Q1 2027 — a modest extension for a company that already carries going-concern doubt. The per-share loss fell to $1.94 from $9.86, reflecting the July 1-for-20 reverse split rather than any improvement in the business. The one thing that could change the story is initial TakeAim CLL data expected in December 2026, with 12 patients enrolled so far.
At the time of this announcement, CRIS was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.33 to $28.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.